RayKnowChina Research Map
Shortlist

RecruitingBreast cancerPhase 3

Registered title, quoted from ClinicalTrials.gov

JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer

An open trial on breast cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteFudan University Shanghai Cancer Center复旦大学附属肿瘤医院ShanghaiHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06846437, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 8

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (8 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. 3.Patients with unresectable locally advanced or metastatic breast cancer confirmed by histology or cytology.

    Inclusion criterion 3

    4.Confirmed to be HER2 positive (HER2-positive is defined as IHC 3+ or IHC 2+ with ISH positive) by the pathology department of participating study center.

    Inclusion criterion 4

    5.Have received treatment regimen including trastuzumab (allowed marketed trastuzumab biosimilars) or inetetamab with radiologic or pathologic progression/ relapse during the advanced stage, during neoadjuvant or adjuvant therapy, or within 12 months after treatment.

    Inclusion criterion 5

    7.Had radiologic and/or pathologic progression or intolerance of the latest systemic anti-tumor therapy.

    Inclusion criterion 7

  3. 1. Have previously been treated with an anti-HER2 ADC loaded with topoisomerase I inhibitors or medenosin derivative 1 (DM1) or have relapsed after receiving such therapy during or within 12 months after the adjuvant/neo-adjuvant setting or in the advanced stage.

    Exclusion criterion 1

  4. 5.Has not recovered from adverse reactions caused by previous anti-tumor treatments to ≤ Grade 1 (refer to NCI CTCAE 5.0) or baseline (excluding grade 2 alopecia, hyperpigmentation, simple laboratory test abnormalities, and other toxicity for a non-safety risk by investigators).

    Exclusion criterion 5

    6.Received immunotherapy, macromolecular targeted therapy or other anti-tumor biological therapy within 4 weeks before randomization, or received palliative radiotherapy, endocrine therapy, cytotoxic drug chemotherapy and small molecular targeted drug therapy within 2 weeks before randomization, or received traditional Chinese medicine preparations with anti-tumor indications within 2 weeks before randomization.

    Exclusion criterion 6

    10.History of LVEF < 40% during prior anti-HER2 drug therapy or symptomatic congestive heart failure (CHF).

    Exclusion criterion 10

    12.History of (non-infectious) interstitial lung disease/pneumonitis requiring therapy or grade ≥3 interstitial lung disease/ pneumonitis during previous anti-tumor treatments.

    Exclusion criterion 12

    16.Received a potent inhibitor of CYP3A4 within 14 days prior to randomization or during study treatment.

    Exclusion criterion 16

  5. 9.ECOG PS of 0 - 1.

    Inclusion criterion 9

  6. 8.At least one extracranial measurable lesion at baseline according to RECIST 1.1 criteria.

    Inclusion criterion 8

  7. 2.History of any other malignant tumors within three years before randomization.

    Exclusion criterion 2

    14. Active hepatitis B or hepatitis C.

    Exclusion criterion 14

    15.History of immunodeficiency or HIV antibody test positive at screening.

    Exclusion criterion 15

  8. 17.Pregnant or nursing females;

    Exclusion criterion 17

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: blood tests: counts, liver and kidney function.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06846437, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • 1. Voluntarily agree to participate in the study and sign the informed consent.
  • 2.Age≥18 years old.
  • 3.Patients with unresectable locally advanced or metastatic breast cancer confirmed by histology or cytology.
  • 4.Confirmed to be HER2 positive (HER2-positive is defined as IHC 3+ or IHC 2+ with ISH positive) by the pathology department of participating study center.
  • 5.Have received treatment regimen including trastuzumab (allowed marketed trastuzumab biosimilars) or inetetamab with radiologic or pathologic progression/ relapse during the advanced stage, during neoadjuvant or adjuvant therapy, or within 12 months after treatment.
  • 6.Previously treated with taxanes.
  • 7.Had radiologic and/or pathologic progression or intolerance of the latest systemic anti-tumor therapy.
  • 8.At least one extracranial measurable lesion at baseline according to RECIST 1.1 criteria.
  • 9.ECOG PS of 0 - 1.
  • 10.Patients with adequate organ and bone marrow functions.
  • 11.Expected survival ≥ 3 months.
  • 12.Female and male patients of childbearing age agree to take adequate contraceptive measures during and upon completion of the study for 7 months after the last dose of JSKN003 or T-DM1.

Exclusion Criteria:

  • 1. Have previously been treated with an anti-HER2 ADC loaded with topoisomerase I inhibitors or medenosin derivative 1 (DM1) or have relapsed after receiving such therapy during or within 12 months after the adjuvant/neo-adjuvant setting or in the advanced stage.
  • 2.History of any other malignant tumors within three years before randomization.
  • 3.With uncontrollable serous effusion within 14 days before randomization, which requires frequent drainage or medical intervention.
  • 4.Known contraindication to T-DM1or not suitable to receive JSKN003 or T-DM1 by investigator.
  • 5.Has not recovered from adverse reactions caused by previous anti-tumor treatments to ≤ Grade 1 (refer to NCI CTCAE 5.0) or baseline (excluding grade 2 alopecia, hyperpigmentation, simple laboratory test abnormalities, and other toxicity for a non-safety risk by investigators).
  • 6.Received immunotherapy, macromolecular targeted therapy or other anti-tumor biological therapy within 4 weeks before randomization, or received palliative radiotherapy, endocrine therapy, cytotoxic drug chemotherapy and small molecular targeted drug therapy within 2 weeks before randomization, or received traditional Chinese medicine preparations with anti-tumor indications within 2 weeks before randomization.
  • 7.Major organ surgery within 28 days before randomization.
  • 8.Untreated (including baseline findings) or unstable cerebral parenchymal metastasis, spinal cord metastasis or compression, and cancerous meningitis.
  • 9.The cumulative amount of previous exposure to anthracyclines has reached the pre-specified dosage.
  • 10.History of LVEF < 40% during prior anti-HER2 drug therapy or symptomatic congestive heart failure (CHF).
  • 11.Serious or uncontrolled cardiovascular disease.
  • 12.History of (non-infectious) interstitial lung disease/pneumonitis requiring therapy or grade ≥3 interstitial lung disease/ pneumonitis during previous anti-tumor treatments.
  • 13.Active infections requiring intravenous antibiotics, antivirals, or antifungals within 14 days before randomization.
  • 14. Active hepatitis B or hepatitis C.
  • 15.History of immunodeficiency or HIV antibody test positive at screening.
  • 16.Received a potent inhibitor of CYP3A4 within 14 days prior to randomization or during study treatment.
  • 17.Pregnant or nursing females;
  • 18.Other reasons enrolled in this clinical trial as considered unsuitable by the investigator.

Quoted from ClinicalTrials.gov, NCT06846437, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06846437, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06846437